(Lentz Therapy, Immunopheresis, UltraPheresis cancer therapy)
- IMMUNOAPHERESIS Refers to the process of antibody cleansing.
- APHERESIS Process in which blood is drawn from a person, separated into various components, then returned to the patients.
- PLASMA Your blood is made up of a liquid portion and a cellular portion. The cellular portion contains white blood cells that fight infection, red blood cells that carry oxygen, and platelets that aid clotting. Plasma is the liquid portion of your blood. It has a number of vital functions in bleeding and infection control. It contains proteins and antibodies, which are produced by the immune system to fight diseases. sTNFRI block the immune system's ability to recognize cancer cells and allow the cancer to grow.
UltraPheresis cancer therapy is based on the use of a blood filtration system developed by Dr. M. Rigdon Lentz, an American oncologist practicing now in Germany.
Simply put, UltraPheresis cleans the blood of decoys which cancer cells use to hide from the immune system. The immune system can then attack and kill cancer cells on its own.
This treatment is effective, safe and non-toxic.
This represents a new paradigm for cancer treatment; many feel it is worthy of the Nobel Prize in medicine.
To find out more about how the EuroMed Foundation uses Lentz therapy for holistic cancer treatment, click here to request your free personal orientation online. One of our doctors will be happy to answer general questions in person or over the phone.
How does UltraPheresis Therapy Work?
The immune system has a surveillance function called the Tumor Necrosis Factor (TNF). The immune system deploys an army of proteins designed to recognize and destroy tumor cells.
But smart cancer cells escape detection. They produce and shed immune system inhibitors into the bloodstream. These inhibitors are called soluble tumor necrosis factor receptors (sTNFR) and these are overproduced in cancer patients.
Dr. Lentz devised a method of treatment, somewhat like kidney dialysis, to remove sTNFRI from the bloodstream.
When plasma is separated from a cancer patient's blood, filtered, then run through a device impregnated with antibodies, these inhibitors are removed, enabling the immune system to attack the tumors. The patient experiences inflammation in the tumors and a flu-like feeling. Over time the tumors shrink, often in short order.
Depending upon the person, this treatment is used as a stand-alone treatment or in conjunction with other cancer treatment alternatives, such as surgery and/or low dose insulin potentiated chemotherapy.
It is widely agreed that cancer is a failure of the immune system. UltraPheresis therapy is an immune system normalizing therapy. It is non-toxic, and straight-forward. It treats close to the root cause of the problem.
At our Arizona cancer center, patients are typically treated for two hours per day, five days per week. Patient progress is continuously monitored. The full treatment generally takes two to three months. The main side-effect of this treatment is pain from the person's own appropriate immune system response destroying the cancer cells.
Dr. Lentz's clinical experience demonstrates that complete tumor destruction is certainly possible through this treatment. He believes the potential for cancer recurrence is decreased. If a cancer recurs, it is responsive to repeating this therapy.
A small amount of inhibitors occupying a normal cell structure.
A cancer cell that has shed a massive amount of tumor necrosis inhibitors to cover itself. Outside the cell, the red item represents the TNF (tumor necrosis factor).
The TNF being made inert through binding of inhibitors.
Dr. M. Rigdon Lentz
This patented technology was developed by American-born and American-trained oncologist Rigdon Lentz, MD. He currently resides in Bavaria, Germany.
Dr. Lentz is affiliated with the Lombardi Center for Immunology at Georgetown University in Washington, D.C. He collaborates with physicians at the Karolinska Institute in Stockholm, Sweden in the research area of tumor immunology. He is the former chief of hematology and oncology at the Comprehensive Cancer Center of Valdosta, GA and the former director of the Nashville, TN, Apheresis Center.
In the late 1980s, Dr. Lentz carried out FDA-supervised Phase I and Phase II studies. In the Proceedings of the National Academy of Sciences, Lentz and colleagues identified, purified, and characterized immune system inhibitors found in the blood of cancer patients.
Dr. Lentz spent two decades investigating the ability of cancer to turn off an otherwise-normal immune system. Attempting to physically remove blocking factors, he custom built a machine that filters them out of the cancer patient's bloodstream.
Dr. Lentz founded Biopheresis Technologies Inc, a U.S. company, and its wholly owned operating company, Biopheresis GmbH, located in Heidelberg, Germany.
In April, 2008, the device received the C.E. Mark ("Conformite Europeenne"). This is a European marking certifying that a product has met EU health, safety, and environmental requirements for consumer safety. At this time, 32 countries recognize the C.E. Mark. The United States does not recognize the C.E. Mark; the FDA is often slow to approve non-toxic treatments and this is one reason so many Americans go to Europe for treatment.
Cancer treatment alternatives to radiation or chemotherapy would be a welcome addition to the arsenal of weapons for the war against cancer. Drug based therapies are based on discovery of molecules to poison or block a single biological event in order to kill a cancer cell. The UltraPheresis treatment however, is based on the removal of soluble immuno-inhibitors known to interfere with the most powerful agent of the body's own innate immune system that acts against cancers, TNF.
The Trophoblastic Thesis
The trophoblastic thesis was first put forward in 1902 by the Scottish embryologist, John Beard. He was among the first to notice that the cancer cells bear a marked resemblance to cells that normally surround the developing embryo called trophoblast cells.
A human being begins with one fertilized cell. It divides and nine months later, that first cell gives rise to entirely different living forms – bones, skin, eyes, hair, organs, etc. However, later in life, each cell has but one function – a liver cell will always be a liver cell.
Trophoblasts, said Beard, are profoundly different. While a normal cell is a good neighbor, the trophoblast is born to be wild. It is primitive, corrosive, and invasive. Sound familiar? Of course: these are the very characteristics of cancer.
One of the mysteries of biology is how and why the embryo survives an immune system that, by all accounts, should kill it on contact because it looks like a foreign invader. Nature has somehow made this trophoblast able to turn off an otherwise vigilant immune system.
Cancer cleverly follows the trophoblast's example, using nature's one big exception to the rule, like a burglar who first turns off a burglar alarm, before he robs the house. Cancer, said Beard, is simply trophoblasts in the wrong place at the wrong time, triggered into malignant life by what we call hormones and carcinogens.
Beard noticed that in various species, trophoblast cells stopped doing the wild thing when the embryo begins to produce pancreatic enzymes. So Beard used pancreatic enzymes in the treatment of advanced cancer. In March, 1909, a man with metastatic sarcoma of the left upper jaw was treated with 120 injections of pancreatic enzymes. By the next year, the man had completely sloughed off the cancer and subsequently remained cancer free.
However, others were unable to reproduce Beard's work, perhaps because he used pancreatic enzymes directly from animals and the others used what was commercially available. Beard's ideas fell by the wayside; he died in obscurity in 1924.
In 1942, Beard's ideas were rediscovered by Ernst T. Krebs, Jr. and his colleagues. In July, 1950, they published an article in the Medical Record on "The Unitarian or Trophoblastic Thesis of Cancer." Krebs believed that "cancer is trophoblast in spatial and temporal anomaly, hybridized with, and vascularized by, hostal or somatic cells and in irreversible and fiercely malignant antithesis to such."
The Nature of Cancer
Cancer is not a foreign invader. The cancerous cells originated from our own native cell population, damaged by environmental agents (ionizing radiation, mercury, sugar, pesticides, formaldehyde, cigarette smoke, chronic viral infections, etc.)
There is also a genetic factor. We often see an increased risk of multiple types of cancer in family members and increased incidence of second sites of cancer in people who survived a first cancer.
Cancer means cells have become defective and the immune system is not on top of the situation.
Healthy mature cells are programmed to divide just so many times in their entire life. This cycle is limited by the number of telomeres on the ends of each strand of DNA. Each time the cell's DNA divides, one telomere is dropped off the end of the DNA. When the DNA runs out of telomeres, no more reproduction is possible and eventually the cell undergoes apoptosis (naturally programmed cell suicide). Cancer cells have a telomerase enzyme that reproduces telomeres; they have an endless supply.
Several therapies used in holistic cancer treatment are aimed at helping with DNA repair. Vitamin A, vitamin D, folic acid, and PolyMVA (palladium alpha lipoic acid) have been used to repair defective DNA.
Some complementary therapies use knowledge of cancer cell weaknesses to kill the cells. Vitamin C for example was promoted by the double Nobel Prize winner, Linus Pauling as a treatment for cancer. Cancer cells lack the healthy ability to gain nourishment from most natural nutrients. Most of cancer's nourishment comes from sugar and cancer cells have many more insulin receptors in order to maximize their sugar uptake. Vitamin C is concentrated in cancer cells by the same mechanism that glucose uses to enter cells, i.e. through insulin stimulation.
Click here to find more information about complementary therapies.
Dr. Lentz wrote that:
"Pregnancy and cancer are the only two biologic conditions in which antigenic tissue is tolerated by a seemingly intact immune system ... trophoblastic tissue has all the characteristics of a true cancer; it is deeply invasive, it is highly anaplastic in morphology, it has a high mitotic index, and it produces oncofetal antigens ... [I]n every respect, [it] behaves as a true cancer."
A "war on cancer" was declared in 1971 by President Richard Nixon. How are we doing? Cancer is expected to be the leading cause of death in the United States by the year 2010. It is the primary cause of death in women between the ages of 35 and 74. Cancer is the chief cause of death in children between the ages of 1 and 14.
From Ralph Moss, PhD, a leading author and consultant on cancer treatment:
"If there were a simple, safe, evidence-based cure for cancer do you think it would make the mainstream ('old') media news today? There is such a cure....It is a really powerful and well-documented cancer therapy that's been around for over 20 years: a simple blood filtration technique developed by oncologist Dr. Rigdon Lentz to remove serum blocking factors produced by the cancer....Remove the blocking factors from the blood and you remove the 'force field' blocking the immune system attack on the cancer. Dramatic tumor 'necrolysis' results."
Doctors belong to a profession whose oath is "First, do no harm."
A Personal Experience:
"I am a 56-yr old woman who was diagnosed with Stage IV metastatic breast cancer two years ago. When conventional treatment failed (I was too far gone for surgery, got chemo for 5 months here in D.C.), I went to Germany for treatment by an American oncologist now working in Prien am Chiemsee, M Rigdon Lentz, who has developed a treatment for soft tissue cancers based on immunotherapy. This is highly scientific, technological in nature... After a year and a half of treatments I am now in clinical remission. Dr. Lentz has just received the CE Mark from the European Union for his device, the technology of which is based on apheresis and the use of antibodies to cancer shed receptors/inhibitors that interfere with TNF response.
This is a treatment that can help thousands of cancer patients in the future. I am only one of a group of people who have come here with a variety of cancer types who now have our cancers under control."
F. Miller, Ph.D.
April 16, 2008
Our Teamwork with Dr. Lentz
We personally work with Dr. Lentz, we have traveled to Germany many times to spend time in his clinic. We have the capability to refer patients to his clinic. We run your preliminary lab tests and ascertain if UltraPheresis cancer therapy would be appropriate for you. If so, we discuss the case with Dr. Lentz and arrange for you to be treated at his clinic.
If you would like to learn more about Lentz therapy and holistic cancer treatment at the EuroMed Foundation, click here to request your free personal orientation online. Or you can call our office at 602-404-0400 to schedule a phone or in-person orientation.
 PNAS 87:8781-8784, 1990; also, Cell 61:361-370, 1990
 Townsend Letter for Doctors, Feb.-March, 1993, p. 175
 Lentz MR. The phylogeny of oncology. Mol Biother 1990;2:137-44.